Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Mutational load distribution analysis (MLDA) in pancreatic cancer

Mutational load distribution analysis (MLDA) in pancreatic cancer

82
Lynch, HenryCreighton University

No coordinating investigator defined.

No involved investigator sites defined.

Ki-ras
UNKNOWN
G.I. and Other Associated Cancers Research Group

Certain p16 mutation carriers showed mutation elevations in the specific Ki-ras and p53 alleles significantly higher than normal, similar to controls with pancreatitis. Two individuals from separate families started out with "low risk" readings subsequently converted to "high risk" categorization and remained there in each sequential exam.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 04/26/2017

A new funding opportunity associated with the Beau Biden Cancer Moonshot Initiative, Integration and Validation of Emerging Technologies to Accelerate Cancer Research, has been released and is due May 10, 2017. Click here for more information.

Announcement 03/14/2017

Thank you to everyone who made the March 2017 EDRN Steering Committee Meeting a success. The next EDRN Steering Committee Meeting will be on September 12-14, 2017, in Seattle, WA.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.